bronchiectasi
heterogen
chronic
respiratori
diseas
character
frequent
respiratori
infect
fact
acut
chronic
respiratori
infect
consid
typic
determin
natur
histori
bronchiectasi
strongli
predict
patient
qualiti
life
diseas
progress
gener
common
belief
exacerb
bronchiectasi
adult
infecti
event
role
exacerb
import
mani
author
defin
bronchiectasi
syndrom
character
perman
bronchial
dilat
recurr
respiratori
infect
exacerb
addit
pathophysiolog
theori
cole
viciou
cycl
explain
develop
bronchiectasi
base
initi
infecti
episod
trigger
local
inflammatori
respons
perman
bronchial
damag
result
viciou
cycl
patient
bronchiectasi
usual
suffer
chronic
airway
inflamm
function
limit
fatigu
dyspnea
recurr
acut
infect
exacerb
chronic
airway
infect
variou
studi
shown
increas
frequenc
exacerb
associ
increas
airway
system
inflamm
progress
lung
damag
addit
sever
ie
requir
hospit
frequent
exacerb
associ
worsen
qualiti
life
daili
symptom
lung
function
declin
mortal
consequ
prognost
score
use
bronchiectasi
sever
exacerb
hospit
sever
exacerb
nine
determin
diseas
sever
assess
face
score
age
chronic
colon
extens
dyspnoea
altern
prognost
score
mortal
risk
recent
updat
includ
exacerb
relev
determin
risk
mortal
futur
exacerb
result
therapeut
intervent
suggest
bronchiectasi
relev
clinic
trial
direct
prevent
exacerb
reduc
frequenc
sever
instanc
influenza
pneumococc
vaccin
continu
use
macrolid
inhal
antibiot
respiratori
physiotherapi
aim
minim
impact
exacerb
patient
qualiti
life
diseas
progress
particular
threshold
three
exacerb
per
year
usual
consid
classifi
patient
unstabl
clinic
condit
consid
continu
inhal
oral
antibiot
take
factor
consider
clear
identif
treatment
prevent
exacerb
crucial
manag
bronchiectasi
line
recent
relev
clinic
trial
inhal
antibiot
use
time
first
exacerb
meanmedian
number
exacerb
primari
outcom
numer
definit
given
far
defin
exacerb
bronchiectasi
includ
acut
chang
cough
sputum
color
viscos
volum
number
addit
symptom
increas
dyspnea
wheez
fatigu
malais
thorac
pain
spirometr
oxygen
worsen
hemoptysi
fever
etc
mani
studi
includ
definit
exacerb
need
antibiot
therapi
accord
decis
attend
physician
criterion
frequent
controversi
assum
bacteri
infect
real
caus
exacerb
administr
antibiot
consequ
definit
part
recent
first
world
bronchiectasi
congress
held
hanov
juli
intern
europ
embarc
usa
australasia
south
africa
task
forc
expert
bronchiectasi
gener
agreedupon
definit
exacerb
bronchiectasi
firstli
review
exacerb
use
clinic
trial
perform
secondli
delphi
process
follow
round
tabl
discuss
use
identifi
relev
element
includ
definit
exacerb
achiev
final
agreement
final
definit
propos
includ
deterior
three
follow
key
symptom
least
h
cough
sputum
volum
andor
consist
sputum
purul
breathless
andor
exercis
toler
fatigu
andor
malais
hemoptysi
clinician
determin
chang
bronchiectasi
treatment
requir
tabl
possibl
futur
need
grade
sever
exacerb
emerg
use
clinic
tool
decid
appropri
therapi
diagnost
test
pneumonia
moment
spanish
guidelin
provid
definit
sever
exacerb
presenc
factor
tachypnea
acut
respiratori
failur
exacerb
chronic
respiratori
failur
signific
declin
respiratori
function
hypercapnia
fever
hemoptysi
hemodynam
instabl
impair
cognit
function
recent
updat
version
spanish
guidelin
introduc
concept
sever
exacerb
character
hemodynam
instabl
alter
mental
statu
need
admit
intens
intermedi
care
unit
tabl
martinezgarcia
et
al
arch
broncopneumol
ahead
print
although
variou
studi
suggest
frequenc
exacerb
greater
four
eventsyear
recent
data
european
bronchiectasi
registri
embarc
shown
major
patient
suffer
two
exacerbationsyear
like
seriou
referr
bia
sicker
patient
special
center
respons
overestim
frequenc
exacerb
howev
worth
mention
patient
might
two
exacerb
year
report
onefourth
patient
might
respons
total
cost
diseas
addit
variou
author
describ
increas
trend
number
hospit
due
bronchiectasi
particular
germani
increas
rate
hospit
report
last
decad
possibl
increas
awar
improv
avail
diagnost
tool
highresolut
ct
scan
contribut
better
identif
bronchiectasi
patient
exacerb
interestingli
research
written
bronchiectasi
exacerb
may
requir
mean
length
hospit
stay
lo
unit
kingdom
day
longer
requir
copd
anoth
public
usa
describ
mean
stay
day
howev
realiz
factor
local
healthcar
organ
socioeconom
aspect
highli
influenc
outcom
reason
difficult
evalu
econom
burden
diseas
measur
mean
length
stay
lo
otherwis
de
la
rosa
et
al
clearli
identifi
frequenc
exacerb
one
main
determin
econom
burden
bronchiectasi
advanc
patient
high
face
score
apart
econom
problem
exacerb
also
neg
influenc
prognosi
fact
variou
longitudin
studi
describ
consider
increas
mortal
risk
exacerb
bronchiectasi
particularli
subset
patient
comorbid
chronic
obstruct
pulmonari
diseas
copd
despit
fact
etiolog
exacerb
alway
clear
bacteria
viru
factor
associ
increas
risk
suffer
exacerb
bronchiectasi
well
describ
broad
radiolog
extens
lobe
bilater
cystic
aspect
moder
sever
bsi
score
anda
histori
recurr
exacerb
last
clear
predictor
exacerb
particular
bsi
score
develop
accord
analysi
risk
factor
hospit
sever
exacerb
need
hospit
independ
predictor
futur
hospit
includ
prior
hospit
admiss
sever
dyspnea
predict
pseudomona
aeruginosa
colon
colon
pathogen
organ
three
lobe
bronchiectasi
two
recent
prognost
score
incorpor
exacerb
origin
face
score
efac
exafac
score
show
better
prognost
capac
improv
risk
classif
chronic
infect
p
aeruginosa
associ
increas
risk
hospit
long
run
mortal
howev
mcdonnel
et
al
also
show
chronic
airway
infect
haemophilu
influenza
increas
outpati
morbid
due
frequent
exacerb
requir
hospit
good
model
risk
stratif
base
airway
microbiom
analysi
stabl
clinic
condit
propos
roger
colleagu
microbiom
analysi
induc
sputum
adult
patient
identifi
three
main
group
p
aeruginosadomin
h
influenzadomin
taxadomin
although
p
aeruginosa
h
influenza
character
poorer
lung
function
well
increas
system
airway
inflamm
p
aeruginosa
final
associ
higher
exacerb
frequenc
confirm
aliberti
et
al
identifi
specif
pseudomona
clinic
phenotyp
cluster
analysi
base
demograph
comorbid
clinic
radiolog
function
microbiolog
data
patient
chronic
p
aeruginosa
show
signific
differ
term
qualiti
life
exacerb
hospit
mortal
followup
compar
chronic
infect
daili
sputum
dri
bronchiectasi
patient
chines
group
develop
specif
score
identifi
patient
bronchiectasi
risk
exacerb
includ
p
aeruginosa
colon
affect
lobe
hrct
scan
prior
icu
admiss
predict
broader
extern
valid
score
would
help
integr
clinic
practic
coexist
copd
asthma
bronchiectasi
patient
wide
recogn
increas
risk
exacerb
particular
metaanalysi
copd
patient
show
bronchiectasi
ct
scan
describ
clear
increas
exacerb
risk
asthmat
patient
associ
bronchiectasi
describ
sever
patient
obstruct
sever
seem
associ
risk
predict
valu
poor
associ
asthma
bronchiectasi
frequent
presenc
aspergillu
sensitiv
case
neutrophil
inflamm
describ
usual
minor
asthma
patient
seem
associ
increas
exacerb
risk
howev
scarc
literatur
clinic
associ
requir
investig
order
defin
clinic
outcom
subset
bronchiectasi
popul
interestingli
british
studi
adult
bronchiectasi
patient
also
identifi
airway
reflux
independ
associ
increas
risk
bronchiectasi
exacerb
year
although
gastroesophag
reflux
report
potenti
etiolog
bronchiectasi
associ
diseas
never
complet
shown
similarli
clear
whether
airway
reflux
real
caus
factor
exacerb
simpli
marker
associ
condit
anoth
factor
consid
term
risk
exacerb
nutrit
statu
well
known
immun
respons
gener
popul
highli
influenc
nutrit
statu
although
relationship
bodi
mass
index
bmi
strong
cystic
fibrosi
longterm
surviv
bronchiectasi
patient
seem
influenc
bmi
chalmer
et
al
describ
associ
vitamin
defici
risk
exacerb
chronic
infect
addit
bmi
associ
increas
mortal
risk
bronchiectasi
lastli
report
region
socioeconom
factor
also
influenc
risk
exacerb
children
adult
popul
tabl
chronic
respiratori
diseas
knowledg
etiolog
exacerb
bronchiectasi
crucial
factor
fact
due
high
impact
exacerb
qualiti
life
longterm
prognosi
bronchiectasi
understand
pathophysiolog
event
sure
improv
manag
diseas
gener
assum
exacerb
due
infect
although
probabl
suffici
scientif
evid
identifi
exacerb
due
caus
treatment
incompli
pulmonari
embol
copd
addit
difficult
distinguish
bacteri
viral
rare
fungal
exacerb
clinic
present
analyt
data
recent
rosal
et
al
identifi
p
aeruginosa
respiratori
virus
staphylococcu
aureu
streptococcu
pneumonia
h
influenza
moraxella
catharrhali
frequent
microorgan
sputum
cultur
nasopharyng
swab
pcr
analysi
virus
exacerb
patient
contrast
atyp
bacteria
seem
infrequ
popul
howev
patient
suffer
pneumonia
show
pneumonia
frequent
isol
irrespect
previou
airway
chronic
infect
studi
identifi
polymicrobi
infect
case
exacerb
pneumon
nonpneumon
two
bacteria
identifi
pneumonia
case
nonpneumon
exacerb
combin
bacteria
viru
found
case
respect
lastli
case
fungal
isol
found
associ
bacteria
role
viral
infect
exacerb
bronchiectasi
also
confirm
previou
studi
adult
children
popul
similar
data
also
report
cf
copd
frequent
virus
describ
exacerb
bronchiectasi
coronaviru
rhinoviru
influenza
viru
b
metapneumoviru
respiratori
syncyti
viru
parainfluenza
howev
mechan
virusinduc
bronchiectasi
exacerb
need
investig
fact
human
model
rhinoviru
infect
shown
abl
impair
ifn
product
neutrophil
inflamm
trigger
copd
exacerb
inflammatori
mechan
induc
secondari
bacteri
infect
pathophysiolog
pattern
clearli
demonstr
bronchiectasi
like
consid
fact
like
copd
airway
inflamm
neutrophil
addit
copd
increas
bacteri
concentr
due
acquisit
new
strain
chronic
h
influenza
describ
caus
exacerb
unfortun
inform
support
theori
bronchiectasi
chang
hostpathogen
interact
could
also
hypothes
exacerb
base
current
evid
microbiom
classic
microbiolog
inflammatori
pattern
fact
tunney
et
al
investig
lung
microbiom
bronchiectasi
patient
surprisingli
found
signific
differ
stabl
condit
exacerb
line
hypothesi
brill
et
al
prefer
defin
bronchiectasi
exacerb
noncf
bronchiectasi
inflammatori
event
worsen
symptom
lung
function
health
statu
nonetheless
clear
scientif
evid
associ
antibiot
administr
consequ
drop
bacteri
load
system
local
inflamm
fact
avail
guidelin
separ
bt
suggest
treat
exacerb
antibiot
therapi
day
exacerb
consid
result
bacteri
infect
current
guidelin
recommend
antibiot
treatment
microbiolog
etiolog
exacerb
quit
variabl
sputum
cultur
suggest
administ
antibiot
order
adjust
treatment
microbiolog
result
howev
presenc
previou
chronic
airway
infect
empir
antibiot
coverag
cover
microorgan
formerli
isol
fact
preliminari
find
multicent
studi
show
rate
concord
microbiolog
chronic
bronchial
infect
exacerb
particularli
case
chronic
p
aeruginosa
contrast
case
pneumonia
microbiolog
etiolog
exacerb
often
differ
stabl
condit
complet
microbiolog
investig
recommend
choic
antibiot
drug
therefor
depend
variou
factor
previou
airway
infect
allergi
intoler
prefer
comorbid
renal
hepat
failur
concomit
medic
well
microbiolog
data
avail
system
antibiot
current
recommend
treatment
exacerb
due
potenti
side
effect
limit
toler
inhal
antibiot
condit
bronchospasm
wheez
cough
administr
rout
oral
intraven
variabl
depend
sever
exacerb
drug
avail
pharmacokinet
patient
characterist
case
h
influenza
amoxicillinclavulan
acid
doxycyclin
fluoroquinolon
levofloxacin
ciprofloxacin
usual
recommend
tabl
case
p
aeruginosa
unfortun
activ
oral
antibiot
ciprofloxacin
gener
use
dosag
mg
bid
altern
intraven
ceftazidim
carbapenem
piperacillintazobactam
cefepim
consid
accord
antibiogram
data
despit
absenc
scientif
evid
regard
use
combin
antibiot
therapi
bronchiectasi
possibl
consid
case
sever
exacerb
mucoid
multidrugresist
strain
p
aeruginosa
particular
combin
therapi
tobramycin
colistin
gentamycin
amikacin
contempl
unfortun
empir
antibiot
coverag
frequent
need
due
unavail
previou
microbiolog
cultur
case
ciprofloxacin
usual
recommend
order
cover
risk
p
aeruginosa
although
recent
diagnos
bronchiectasi
patient
previou
exacerb
amoxicillinclavulan
also
consid
highli
recommend
perform
sputum
cultur
antibiot
administr
order
eventu
adjust
antibiot
therapi
microbiolog
result
becom
avail
tabl
base
clinic
practic
expert
opinion
certain
scientif
evid
day
antibiot
therapi
usual
recommend
howev
case
mild
exacerb
prompt
resolut
symptom
fewer
day
potenti
viral
infect
shorten
antibiot
cours
could
consid
howev
clinic
followup
could
use
ensur
complet
recoveri
similarli
case
late
partial
treatment
respons
longer
antibiot
therapi
could
consid
although
treatment
failur
suspect
clinic
worsen
despit
antibiot
therapi
insuffici
improv
end
antibiot
cycl
new
microbiolog
investig
perform
noninfecti
caus
clinic
deterior
pulmonari
embol
heart
failur
investig
case
high
fever
creactiv
protein
mgdl
unusu
find
upon
thorac
auscult
pneumonia
rule
chest
xray
ct
scan
risk
pneumonia
cover
also
microorgan
respons
preexist
chronic
bronchial
infect
need
consid
specif
recommend
regard
corticosteroid
inhal
bronchodil
exacerb
bronchiectasi
use
usual
follow
gener
indic
drug
regard
inhal
hyperosmolar
agent
hyperton
salin
mannitol
scientif
evid
support
use
exacerb
moreov
risk
side
increas
exacerb
due
increas
airway
inflamm
gener
widespread
doctor
airway
clearanc
techniqu
facilit
acceler
patient
recoveri
exacerb
unfortun
evid
airway
clearanc
techniqu
use
exacerb
facilit
acceler
patient
recoveri
investig
sure
need
futur
longterm
manag
bronchiectasi
gener
direct
prevent
exacerb
therefor
numer
recommend
appear
spanish
british
guidelin
particular
use
chronic
oral
macrolid
inhal
antibiot
wide
support
expert
worldwid
sinc
number
interest
trial
provid
increas
scientif
evid
therapi
particular
three
major
random
clinic
trial
bless
embrac
bat
show
clear
reduct
exacerb
time
first
exacerb
frequenc
exacerb
continu
use
azithromycin
mg
daili
mg
time
week
erythromycin
mg
bid
despit
methodolog
differ
trial
three
provid
common
evid
recommend
use
antibiot
case
patient
three
exacerb
previou
year
despit
optim
therapeut
manag
worth
mention
import
advers
event
report
far
particular
diarrhea
increas
proport
macrolideresist
microorgan
oropharyng
mucosa
streptococci
quit
common
less
frequent
potenti
treatmentrel
advers
event
qtc
prolong
tinnitushear
loss
select
macrolid
resist
nontubercul
mycobacteria
ntm
care
consid
begin
longterm
treatment
macrolid
particular
sputum
cultur
neg
ntm
recommend
begin
macrolid
sinc
known
ntm
infect
caus
macrolideresist
strain
usual
difficult
treat
convers
chronic
regimen
oral
antibiot
amoxicillin
tetracyclin
report
improv
sputum
purul
show
clear
benefit
term
exacerb
frequent
macrolid
clinic
expert
bronchiectasi
feel
inhal
antibiot
potenti
best
option
reduc
exacerb
bronchiectasi
due
high
local
concentr
achiev
airway
minim
system
side
effect
limit
occurr
antibiot
resist
numer
antibiot
develop
past
year
inhal
administr
eg
dri
powder
nebul
solut
includ
ciprofloxacin
aztreonam
colistin
tobramycin
unfortun
level
evid
support
use
clinic
practic
still
controversi
due
fact
unexpectedli
clinic
trial
fail
achiev
primari
outcom
instanc
inhal
aztreonam
shown
posit
result
cf
improv
qualiti
life
primari
outcom
lqb
questionnair
significantli
placebo
haworth
et
al
could
prove
inhal
colistin
could
significantli
prolong
time
first
exacerb
overal
popul
primari
outcom
howev
patient
stay
treatment
trial
show
median
time
exacerb
vs
day
colistin
placebo
group
respect
p
similar
result
describ
studi
investig
efficaci
nebul
liposom
ciprofloxacin
bronchiectasi
patient
p
aeruginosa
infect
singl
blind
studi
nebul
gentamicin
show
signific
reduct
frequenc
exacerb
vs
p
compar
salinetr
patient
prolong
time
first
exacerb
vs
p
phase
ii
rct
investig
inhal
ciprofloxacin
dri
powder
show
promis
result
term
microbiolog
respons
result
subsequ
longterm
phase
iii
rct
current
await
relev
side
effect
describ
associ
use
inhal
antibiot
increas
cough
bronchospasm
breathless
minim
nonsignific
antimicrobi
resist
current
known
recent
european
guidelin
bronchiectasi
suggest
use
inhal
antibiot
prevent
exacerb
patient
chronic
p
aeruginosa
infect
use
macrolid
prevent
exacerb
patient
chronic
airway
infect
although
individu
approach
alway
consid
despit
fact
hyperton
salin
prove
improv
airway
clearanc
qualiti
life
bronchiectasi
combin
respiratori
physiotherapi
still
evid
chronic
use
prevent
exacerb
consid
promis
result
low
cost
intervent
investig
sure
urgent
need
expens
hyperosmolar
agent
mannitol
fail
show
signific
reduct
annual
frequenc
exacerb
primari
outcom
rate
ratio
p
howev
compar
lowdos
mannitol
control
mannitol
prolong
time
first
exacerb
hr
p
qualiti
life
unit
p
two
secondari
outcom
luckili
similar
side
effect
report
arm
otherwis
deoxyribonucleas
rhdnase
current
contraind
bronchiectasi
due
fact
rct
show
increas
rate
exacerb
associ
mucolyt
agent
frequent
use
cf
although
respiratori
physiotherapi
current
recommend
exacerb
use
stabl
clinic
condit
consid
pillar
longterm
manag
bronchiectasi
ideal
excel
physiotherapi
includ
airway
clearanc
techniqu
andor
pulmonari
rehabilit
abl
reduc
mucu
retent
limit
accumul
microorgan
inflammatori
cell
molecul
therefor
physiotherapi
abl
disrupt
cole
viciou
cycl
perpetu
lung
damag
bronchiectasi
unfortun
scientif
evid
regard
airway
clearanc
techniqu
extrem
heterogen
due
variou
method
intervent
outcom
measur
heterogen
make
almost
imposs
suggest
standard
protocol
airway
clearanc
nonetheless
numer
studi
indic
advantag
regular
physiotherapi
sputum
volum
impact
cough
qualiti
life
airway
clearanc
techniqu
especi
indic
patient
copiou
phlegm
andor
difficult
expector
intervent
person
base
patient
characterist
prefer
well
avail
physiotherapist
andor
devic
herrerocortina
et
al
compar
autogen
drainag
techniqu
perform
autonom
patient
eltgol
requir
intervent
physiotherapist
uniko
temporari
positiveexpiratorypressur
tpep
devic
popul
stabl
bronchiectasi
patient
could
demonstr
three
intervent
achiev
similar
result
enhanc
mucu
clearanc
treatment
session
reduc
expector
rest
day
evid
avail
regard
efficaci
pulmonari
rehabilit
improv
exercis
capac
trend
toward
better
qualiti
life
lee
et
al
perform
random
control
trial
aim
investig
effect
exercis
train
airway
clearanc
techniqu
exercis
capac
qualiti
life
hrqol
incid
acut
exacerb
bronchiectasi
studi
found
literatur
show
physiotherapi
abl
reduc
dyspnea
increas
exercis
capac
also
reduc
incid
exacerb
year
copd
cf
regular
perform
physic
activ
pulmonari
physiotherapi
recommend
patient
bronchiectasi
order
reduc
overal
burden
diseas
term
respiratori
symptom
dyspnea
fatigu
cough
expector
reduc
frequenc
sever
exacerb
like
physiotherapeut
intervent
use
bronchiectasi
optim
person
specif
patient
health
condit
recent
european
guidelin
recommend
use
hyperton
salin
mannitol
bronchiectasi
patient
chronic
product
cough
difficulti
expector
sputum
rehabilit
case
impair
exercis
capac
unfortun
data
regard
efficaci
influenza
pneumococc
vaccin
specif
popul
bronchiectasi
nevertheless
incid
bronchiectasi
increas
exponenti
elderli
gener
recommend
use
vaccin
influenza
viru
pneumococc
infect
peopl
year
old
particularli
case
chronic
respiratori
diseas
moreov
well
known
bronchiectasi
patient
suffer
pneumonia
gener
popul
sinc
first
caus
communityacquir
pneumonia
bronchiectasi
pneumonia
wise
recommend
pneumococc
vaccin
patient
order
reduc
respiratori
morbid
polysaccharid
vaccin
wide
histor
use
bronchiectasi
investig
immun
respons
antibodi
product
conjug
vaccin
introduc
last
year
due
recogn
superior
term
reduc
risk
pneumococc
pneumonia
prolong
durat
protect
tcellmedi
immunolog
memori
nevertheless
tailor
research
need
futur
better
develop
strategi
prevent
infect
subset
popul
bronchiectasi
